Expert Review of Anticancer Therapy

Papers
(The TQCC of Expert Review of Anticancer Therapy is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence80
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma76
Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?41
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia40
Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review35
PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects30
Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma30
Oral decitabine and cedazuridine for the treatment of myelodysplastic syndromes: an integrated review of clinical, economic and patient-centered evidence28
The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs28
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review27
Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancer27
Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis25
Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma24
2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma23
Progress in the development of tissue-based biomarkers for urothelial cancer23
Current status and novel insights into the role of metastasectomy in the era of immunotherapy22
Current management of familial adenomatous polyposis22
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan21
Progress in histology specific treatments in soft tissue sarcoma21
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer21
Primary effusion lymphoma: therapeutic strategies targeting viral and cellular mechanisms19
Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population17
Prostate cancer prediction through a hybrid deep learning method applied to histopathological image16
Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: multicentre experience in a low-middle-income country15
Supportive care in pediatric acute myeloid leukemia:Expert-based recommendations of the NOPHO-DB-SHIP consortium15
Early detection of hepatocellular carcinoma: roadmap for improvement15
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer14
NRF2/KEAP1 signaling inhibitors in gynecologic cancers14
Outcomes after the watch-and-wait strategy and local excision treatment for rectal cancer: a meta-analysis13
Current status of robotic surgery for hepato-pancreato-biliary malignancies13
An evaluation of selinexor as a maintenance therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma13
A systematic review to summarize treatment patterns, guidelines, and characteristics of patients with renal cell carcinoma in the Asia-Pacific region13
Deciding individual treatment for primary retroperitoneal sarcoma13
Diagnostic significance of miRNAs as potential biomarkers for human renal cell carcinoma: a systematic review and meta-analysis13
Management of breast cancer diagnosed during pregnancy: global perspectives13
What are the key considerations for deciding on the use of CAR T-cell therapy for patients with follicular lymphoma?12
Targeting GPRC5D in multiple myeloma12
The trend toward more target therapy in pancreatic ductal adenocarcinoma11
Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC)11
Differentiated thyroid cancer and positron emission computed tomography: when, how and why?11
Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives11
Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: a meta-analysis and systematic review11
Novel breakthroughs in advanced prostate cancer management11
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond11
Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer11
Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and 11
NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?11
The long and winding road of faecal microbiota transplants to targeted intervention for improvement of immune checkpoint inhibition therapy11
PROTACs in action: a novel strategy for pancreatic cancer10
Efficacy and safety of anti-angiogenesis agents combined with chemoradiotherapy in the treatment of locally advanced cervical cancer: a meta-analysis of randomized controlled trials10
Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity10
Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer10
Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care?10
Anticancer properties of histone deacetylase inhibitors – what is their potential?10
The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer10
Nivolumab plus ipilimumab in malignant pleural mesothelioma10
Benign and malignant cardiac masses: long-term outcomes after surgical resection9
A neurocentric model of survivorship: rethinking success when the mind and nerves don’t recover9
Pembrolizumab in the first-line treatment of advanced head and neck cancer9
Genetic investigation in patients with histological variants of bladder cancer: clinical implications9
Interventions to reduce the risk of side-effects of cancer treatments in childhood9
Emerging treatment options for prostate cancer9
Drug–drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors9
Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy9
JARID2 activation by NFYA promotes stemness of triple-negative breast cancer cells through the PI3K/AKT pathway9
Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation9
What’s to come in PSMA therapies and diagnostics: A summary of clinical trials involving PSMA radioligand-based therapeutic and/or diagnostic approaches with active recruitment9
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials9
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)8
Effect of flexible sigmoidoscopy-based screening on colorectal cancer incidence and mortality: an updated systematic review and meta-analysis of randomized controlled trials8
Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials8
Image-guided radiotherapy (IGRT) in Lombardy, Italy: a survey by the Lombardy section of the Italian Association of Radiotherapy and Clinical Oncology (AIRO-Lombardy)8
Radiation-induced nasopharyngeal necrosis combined with local recurrence in nasopharyngeal carcinoma: diagnosis and treatment strategies8
Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma8
Cemiplimab for locally advanced and metastatic basal cell carcinoma8
LAG-3 is a promising inhibitory immune checkpoint for antitumor immunotherapy8
Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer8
Clinicopathological and prognostic significance of TIMP1 expression in gastric cancer: a systematic review and meta-analysis8
Oligometastases in head and neck squamous cell carcinoma patients8
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer8
Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers8
Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty8
Molecular-driven treatment for biliary tract cancer: the promising turning point8
Girentuximab imaging in renal cancer: diamond in the rough or just ZIRCON?8
The Gustave Roussy immune score as a novel biomarker for predicting survival in patients with isocitrate dehydrogenase wild-type glioblastoma treated with the Stupp protocol7
Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review7
Venetoclax and beyond: New Horizons in CLL and AML therapy7
Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer7
Circadian rhythm-based cancer therapy in randomised clinical trials7
Medullary thyroid carcinoma: a narrative historical review7
From supportive care to adjunctive treatment: the evolution in time of physical exercise and nutrition in lung cancer7
Immune checkpoint inhibition in early-stage triple-negative breast cancer7
The selection of targeted therapies for relapsed or refractory advanced renal cell carcinoma7
Shedding light on the side effects of immunotherapies used for leukemia: an updated review of the literature7
Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy7
The current treatment approach to adolescents and young adults with acute lymphoblastic leukemia (AYA-ALL): challenges and considerations7
Management of oligometastatic and oligoprogressive renal cell carcinoma: an updated review7
Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment7
Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?7
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?7
Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?7
Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia7
Is 2045 the best we can do? Mitigating the HPV-related oropharyngeal cancer epidemic7
Contemporary management of advanced gastric and gastroesophageal adenocarcinomas7
The association between HALP score and survival in patients treated with immune checkpoint inhibitors7
Overcoming common emerging barriers to effective neoadjuvant immunotherapies6
Inhibition of neuroactive ligand–receptor interaction pathway can enhance immunotherapy response in colon cancer: an in silico study6
Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going?6
Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis6
Efficacy of doxorubicin and lipiodol therapy by trans-arterial chemoembolization in hepatocellular carcinoma Egyptian patients and relation to genetic polymorphisms6
Mucosa-associated lymphoid tissue lymphoma in thymus: a SEER analysis6
First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC6
Ablative margins in percutaneous thermal ablation of hepatic tumors: a systematic review6
Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancer6
Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitors6
Integrating PET/CT into breast cancer care: a review of recent developments6
Predicting neoadjuvant chemoradiotherapy response with functional imaging and liquid biomarkers in locally advanced rectal cancer6
Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review6
The relationship between statin use and breast cancer risk: NHANES 2003–2016 and Mendelian randomization study6
Inside prostate cancer news from the 2021 ASCO Genitourinary Cancers Symposium6
The assessment of circulating tumor DNA associated with Wnt/β-catenin signaling pathway as a diagnostic tool for liver cancer: a systematic review and meta-analysis6
Reevaluating the promise: is primary tumor surgery really the key to survival or just a misinterpretation in de novo stage IV breast cancer?6
Primary site and treatment impact in unresectable metastatic colorectal cancer6
Addressing the need for more therapeutic options in neuroendocrine prostate cancer6
Factors influencing survival in metastatic castration-resistant prostate cancer therapy5
Cancer immunotherapy efficacy and machine learning5
Efficacy and safety of neoadjuvant therapy for triple-negative breast cancer: a Bayesian network meta-analysis5
FLT3 -mutated AML: immune evasion through exosome-mediated mechanisms and innovative combination therapies targeting immune escape5
Diagnostic performance of urine and blood microRNAs for bladder cancer: a meta-analysis5
Is the ketogenic diet still controversial in cancer treatment?5
The optimal management of brain metastases from gestational trophoblastic neoplasia5
The Wnt/β-catenin pathway in breast cancer therapy: a pre-clinical perspective of its targeting for clinical translation5
Surgical management of intrahepatic cholangiocarcinoma5
Immune checkpoint inhibitors for recurrent endometrial cancer5
Clarifications and comments on “infrared radiation for cancer hyperthermia: the light to brighten up oncology”5
Analysis of the efficacy of paclitaxel combined with bevacizumab intraperitoneal instillation in common gastrointestinal malignant peritoneal effusions and screening of prognostic indicators5
Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis5
How can we refine the prognostic stratification of triple-negative breast cancer?5
Drug-induced pulmonary toxicity in breast cancer patients treated with systemic therapy: a systematic literature review5
The investigational role of cytoreductive stereotactic ablative radiation therapy (SABR) to the primary tumor in metastatic kidney cancer5
The role of planetary health in urologic oncology5
Immune senescence in non-small cell lung cancer management: therapeutic relevance, biomarkers, and mitigating approaches5
Therapeutic patterns and outcomes in older patients (aged≥65 years) with stage III-IVB inoperable oral cavity squamous cell carcinoma (OCSCC): an investigational study from the SEER database5
Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer – a review of current evidence for and against the use of anti-HER2 treatment regimens5
The multidisciplinary management of locally advanced rectal cancer5
Prognostic value of circulating long non-coding RNAs in colorectal cancer patients: a meta-analysis5
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma5
Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for gastric cancer treatment: a systematic review and meta-analysis5
Development of a nomogram for predicting postoperative recurrence of cervical intraepithelial neoplasia using immunohistochemical and clinical parameters5
Relugolix in the management of prostate cancer5
0.087031841278076